CN116687941A - 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法 - Google Patents

用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法 Download PDF

Info

Publication number
CN116687941A
CN116687941A CN202310102470.8A CN202310102470A CN116687941A CN 116687941 A CN116687941 A CN 116687941A CN 202310102470 A CN202310102470 A CN 202310102470A CN 116687941 A CN116687941 A CN 116687941A
Authority
CN
China
Prior art keywords
cpx
ciclopirox
pom
bladder cancer
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310102470.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·韦尔
S·南特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Publication of CN116687941A publication Critical patent/CN116687941A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310102470.8A 2014-11-11 2015-11-10 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法 Pending CN116687941A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462078069P 2014-11-11 2014-11-11
US62/078,069 2014-11-11
US201562134747P 2015-03-18 2015-03-18
US62/134,747 2015-03-18
PCT/US2015/059955 WO2016077346A1 (en) 2014-11-11 2015-11-10 Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug
CN201580061284.8A CN107206012A (zh) 2014-11-11 2015-11-10 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580061284.8A Division CN107206012A (zh) 2014-11-11 2015-11-10 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法

Publications (1)

Publication Number Publication Date
CN116687941A true CN116687941A (zh) 2023-09-05

Family

ID=55954945

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310102470.8A Pending CN116687941A (zh) 2014-11-11 2015-11-10 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法
CN201580061284.8A Pending CN107206012A (zh) 2014-11-11 2015-11-10 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580061284.8A Pending CN107206012A (zh) 2014-11-11 2015-11-10 用环吡酮、环吡酮胺或环吡酮前药治疗膀胱癌的方法

Country Status (11)

Country Link
US (1) US20170304329A1 (https=)
EP (1) EP3217980B1 (https=)
JP (1) JP2017533952A (https=)
CN (2) CN116687941A (https=)
DK (1) DK3217980T3 (https=)
ES (1) ES2836208T3 (https=)
HR (1) HRP20201893T1 (https=)
HU (1) HUE052670T2 (https=)
PT (1) PT3217980T (https=)
RS (1) RS61222B1 (https=)
WO (1) WO2016077346A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112351970A (zh) * 2018-05-30 2021-02-09 科莱恩国际有限公司 2-羟基吡啶-1-氧化物或其衍生物的形成方法
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
WO2021078937A1 (en) * 2019-10-25 2021-04-29 Deutsches Krebsforschungszentrum Treatment of stat3 related diseases by iron chelators
EP4193989A1 (en) 2021-12-09 2023-06-14 Atlas Molecular Pharma, S.L. A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007676A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
US20120142637A1 (en) * 2010-12-02 2012-06-07 The University Of Kansas Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1h)- one and derivatives thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US20110212176A1 (en) 2008-10-31 2011-09-01 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
EP2576513A1 (en) * 2010-06-01 2013-04-10 Biotheryx Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007676A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
US20120142637A1 (en) * 2010-12-02 2012-06-07 The University Of Kansas Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1h)- one and derivatives thereof

Also Published As

Publication number Publication date
WO2016077346A1 (en) 2016-05-19
HUE052670T2 (hu) 2021-05-28
EP3217980A4 (en) 2018-05-02
CN107206012A (zh) 2017-09-26
US20170304329A1 (en) 2017-10-26
PT3217980T (pt) 2020-12-11
RS61222B1 (sr) 2021-01-29
JP2017533952A (ja) 2017-11-16
ES2836208T3 (es) 2021-06-24
DK3217980T3 (da) 2020-12-07
EP3217980B1 (en) 2020-10-14
HRP20201893T1 (hr) 2021-02-05
EP3217980A1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
US9545413B2 (en) Methods of forming ciclopirox or derivatives thereof in a subject by administration of prodrug
CN104363913B (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
US10450305B2 (en) LKB1-AMPK activators for therapeutic use in polycystic kidney disease
EP3217980B1 (en) Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
US20200102264A1 (en) Marmelin analogs and methods of use in cancer treatment
CN113143965A (zh) 一种抑制肿瘤增殖的氨基富勒烯材料
CN101302199B (zh) 桂德霉素及其在制备抗肿瘤药物中的应用
US20060194829A1 (en) Therapeutic materials and methods
CN115244064A (zh) 治疗性分子的靶向递送
KR20250007465A (ko) Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
WO2024077358A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones.
JP7345167B2 (ja) ポリ（カルバメート）－核酸医薬コンジュゲート、ポリ（カルバメート）核酸医薬コンジュゲートの凝集粒子、及び凝集粒子の製造方法
WO2025194120A1 (en) Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids
JP4353425B2 (ja) システイン高組成ペプチド
KR20150036215A (ko) 퀴논 화합물 및 암의 치료를 위한 그것의 용도
Cassidy et al. 370 POSTER Once weekly rIL-21 in combination with cetuximab as 1st line therpay in CRC. A dose finding safety trial

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230905

WD01 Invention patent application deemed withdrawn after publication